Cancer Biomarker Detection With Luminex Assays

Luminex and Bio-Techne are working together to support the development of early diagnostic solutions that detect cancer earlier through the use of proteomics.
Charles Rosser, a research scientist and professor of biomedical sciences, has developed a multiplex test for early-stage bladder cancer using Luminex® xMAP® Technology. Bladder cancer affects over 570,000 people globally each year, and the Oncuria® test aims to detect bladder cancer, monitors for recurrence, and predicts which patients will benefit from the immunotherapy treatment. Current diagnostic assays lack sensitivity and do not provide a comprehensive view of the cancer’s molecular profile, but the Oncuria® test covers 10 glycoproteins to detect the biological signature of bladder cancer with sensitivity of 90% to 93% and specificity of 86% to 95%. The test received Breakthrough Device Designation status from the FDA and is currently available as a laboratory-developed test (LDT). In a recent clinical validation study involving about 350 patients, the test offered 93% sensitivity. Learn more about this major shift in the care of patients with bladder cancer.

MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel 3 - Cancer Multiplex Assay Circulating Cancer Biomarker

Multiplex Cancer Assays for Cancer Biomarker Detection

Luminex Discovery Assays R&D Systems, a Bio-Techne Brand

Luminex Cytokine Detection Service - Creative Proteomics

PPT - Ovarian Cancer Early Detection Biomarkers Trials and Regulatory Issues PowerPoint Presentation - ID:9424967

Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy

Autoantibodies as Biomarkers in Immuno-Oncology

Multiplexed cancer biomarker detection using chip-integrated silicon photonic sensor arrays - Analyst (RSC Publishing) DOI:10.1039/C6AN01076H

Multiplexed Profiling of Extracellular Vesicles for Biomarker Development

Improving Cancer Detection with Proteomics

Luminex™ bead-based immunoassays drive immunoassays towards higher-content biomarker discovery - Behind the Bench